Reversing the standard approved dose levels of nivolumab (Opdivo) and ipilimumab (Yervoy) in metastatic melanoma led to less ...

Bristol Myers Squibb and its subsidiary Karuna Therapeutics received the latest Untitled Letter from the Food and Drug Administration earlier this week. In a letter issued on December 15 to Nicole Van ...

Bristol Myers Squibb has won Food and Drug Administration priority review for its application seeking expanded approval of its blockbuster cancer drug Opdivo, in combination with chemotherapy, in ...

Oct 30 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab beat Wall Street estimates for third-quarter revenue on Thursday, as strong growth of its cancer immunotherapy and blood thinner Eliquis ...

Opdivo showed superior long-term efficacy over Yervoy in resected stage 3B-4 melanoma, with improved RFS and DMFS outcomes. Median OS and MSS were not reached, but data favored Opdivo, suggesting a ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved the Idylla CDx MSI test — a fully automated, “sample-to-result” companion diagnostic — for ...

Challenges to two patents covering dosing options for Bristol-Myers Squibb Co. ‘s blockbuster Opdivo cancer drug were turned away by the US Patent and Trademark Office, continuing the agency’s move to ...

A more gradual titration significantly reduced the incidence of amyloid-related imaging abnormalities with edema/effusion. The Food and Drug Administration (FDA) has updated the labeling for Kisunla ™ ...

The FDA narrowed the indications for pembrolizumab (Keytruda) and nivolumab (Opdivo) in gastric, gastroesophageal junction (GEJ), and esophageal cancers, according to letters sent to the respective ...

When it comes to the use of PD-1 inhibitors in stomach cancer, the FDA has put its money where its mouth is. After questioning the benefits of checkpoint inhibitors in stomach cancer cases without ...